HomeAI · summaries
Storia in 20 fonti
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treatment.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
en.mercopress.com
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…
- ·
healio.com
mRNA melanoma vaccine-pembrolizumab combo shows survival gains in late-stage trial
A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk…
